PCI Biotech Holding is developing a light-directed drug delivery system with the potential to make drug delivery more efficient and targeted, and to reduce overall toxicity. The company's technology is based on the fact that cells absorb molecules, including proteins and other biological macromolecules, drug carriers such as antibodies and nanoparticles, and some small molecules, by engulfing them with the cell membrane, in a process called endocytosis. This creates an endosome, a small "bubble" of cell membrane enclosing the absorbed molecules. For the biologically active molecules to interact with the intracellular targets, they must be released from the endosome into the cytosol in a process called "endosomal escape."
Hoffsveien 48
N-0377 Oslo, Norway
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The UK major's asthma drug gets a key expanded approval.
Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.
Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list
